Cargando…
Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer
The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents. 1,25D and its analogs have potential in combination therapies be...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038752/ https://www.ncbi.nlm.nih.gov/pubmed/35468986 http://dx.doi.org/10.1038/s41598-022-10740-9 |
_version_ | 1784693972205043712 |
---|---|
author | Barbier, Camille Mansour, Ali Ismailova, Aiten Sarmadi, Fatemeh Scarlata, David A. Bouttier, Manuella Zeitouni, Camille Wang, Catherine Gleason, James L. White, John H. |
author_facet | Barbier, Camille Mansour, Ali Ismailova, Aiten Sarmadi, Fatemeh Scarlata, David A. Bouttier, Manuella Zeitouni, Camille Wang, Catherine Gleason, James L. White, John H. |
author_sort | Barbier, Camille |
collection | PubMed |
description | The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents. 1,25D and its analogs have potential in combination therapies because they exhibit synergistic activities with other anticancer agents such as histone deacetylase inhibitors (HDACi). We have developed a series of hybrid molecules that combine HDACi within the backbone of a VDR agonist and thus represent fully integrated bifunctional molecules. They exhibit anti-tumor efficacy in reducing tumor growth and metastases in an aggressive model of triple-negative breast cancer. However, their solubility is limited by their hydrophobic diarylpentane cores. Our goals here were two-fold: (1) to improve the solubility of hybrids by introducing nitrogen into diarylpentane cores, and (2) to investigate the molecular mechanisms underlying their anti-tumor efficacy by performing comparative gene expression profiling studies with 1,25D and the potent HDACi suberoylanilide hydroxamic acid (SAHA). We found that substituting aryl with pyrydyl rings did not sacrifice bifunctionality and modestly improved solubility. Notably, one compound, AM-193, displayed enhanced potency as a VDR agonist and in cellular assays of cytotoxicity. RNAseq studies in triple negative breast cancer cells revealed that gene expression profiles of hybrids were very similar to that of 1,25D, as was that observed with 1,25D and SAHA combined. The effects of SAHA alone on gene expression were limited and distinct from those 1,25D or hybrids. The combined results suggest that efficacy of hybrids arises from targeting HDACs that do not have a direct role in gene regulation. Moreover, pathways analysis revealed that hybrids regulate numerous genes controlling immune cell infiltration into tumors and suppress the expression of several secreted molecules that promote breast cancer growth and metastasis. |
format | Online Article Text |
id | pubmed-9038752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90387522022-04-27 Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer Barbier, Camille Mansour, Ali Ismailova, Aiten Sarmadi, Fatemeh Scarlata, David A. Bouttier, Manuella Zeitouni, Camille Wang, Catherine Gleason, James L. White, John H. Sci Rep Article The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents. 1,25D and its analogs have potential in combination therapies because they exhibit synergistic activities with other anticancer agents such as histone deacetylase inhibitors (HDACi). We have developed a series of hybrid molecules that combine HDACi within the backbone of a VDR agonist and thus represent fully integrated bifunctional molecules. They exhibit anti-tumor efficacy in reducing tumor growth and metastases in an aggressive model of triple-negative breast cancer. However, their solubility is limited by their hydrophobic diarylpentane cores. Our goals here were two-fold: (1) to improve the solubility of hybrids by introducing nitrogen into diarylpentane cores, and (2) to investigate the molecular mechanisms underlying their anti-tumor efficacy by performing comparative gene expression profiling studies with 1,25D and the potent HDACi suberoylanilide hydroxamic acid (SAHA). We found that substituting aryl with pyrydyl rings did not sacrifice bifunctionality and modestly improved solubility. Notably, one compound, AM-193, displayed enhanced potency as a VDR agonist and in cellular assays of cytotoxicity. RNAseq studies in triple negative breast cancer cells revealed that gene expression profiles of hybrids were very similar to that of 1,25D, as was that observed with 1,25D and SAHA combined. The effects of SAHA alone on gene expression were limited and distinct from those 1,25D or hybrids. The combined results suggest that efficacy of hybrids arises from targeting HDACs that do not have a direct role in gene regulation. Moreover, pathways analysis revealed that hybrids regulate numerous genes controlling immune cell infiltration into tumors and suppress the expression of several secreted molecules that promote breast cancer growth and metastasis. Nature Publishing Group UK 2022-04-25 /pmc/articles/PMC9038752/ /pubmed/35468986 http://dx.doi.org/10.1038/s41598-022-10740-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Barbier, Camille Mansour, Ali Ismailova, Aiten Sarmadi, Fatemeh Scarlata, David A. Bouttier, Manuella Zeitouni, Camille Wang, Catherine Gleason, James L. White, John H. Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer |
title | Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer |
title_full | Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer |
title_fullStr | Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer |
title_full_unstemmed | Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer |
title_short | Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer |
title_sort | molecular mechanisms of bifunctional vitamin d receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038752/ https://www.ncbi.nlm.nih.gov/pubmed/35468986 http://dx.doi.org/10.1038/s41598-022-10740-9 |
work_keys_str_mv | AT barbiercamille molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer AT mansourali molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer AT ismailovaaiten molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer AT sarmadifatemeh molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer AT scarlatadavida molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer AT bouttiermanuella molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer AT zeitounicamille molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer AT wangcatherine molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer AT gleasonjamesl molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer AT whitejohnh molecularmechanismsofbifunctionalvitamindreceptoragonisthistonedeacetylaseinhibitorhybridmoleculesintriplenegativebreastcancer |